Meet with ICON experts at the GLP-1-Based Therapeutics Summit to gain valuable insights on obesity clinical development and learn about our ready-to-deploy infrastructure designed to accelerate obesity and comorbidity pr...

Earlier this month, our teams across ICON came together around the world to celebrate International Women’s Day. From team celebrations and office events to shared moments of reflection, this year’s theme, Give to Gain,...

Accellacare, ICON’s clinical research network, offers a wide range of stand-alone and integrated solutions to increase patient access to innovative treatments. Meet us at #WorldVaccineCongress, booth 222 to learn how o...

Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - \~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pre...

Attending World Vaccine Congress? Join ICON’s Dinah Knotts-Keeterle on 1 April at 12:10 pm as she discusses on ‘AI and the future of vaccine studies from reaction to readiness’. Learn more. https://ow.ly/GzT350Yr8Y8

Join Thanh-Long Nguyen and other industry experts to discuss the latest developments in flow cytometry. This panel hosted by Bioanalysis Zone will explore how innovation is reshaping assay development and clinical trial ...

As the CRA role evolves, so do the opportunities for career progression. From In-House CRA to Clinical Trial Manager, Huseyin's journey highlights how roles are expanding and creating new opportunities for growth. Regi...

Thank you to everyone who joined our Rare Disease Day webinar. The inspiring discussion highlighted the results of patients’ and parents’ relentless advocacy, including scientific breakthroughs and regulatory progress in...

Flow cytometry is evolving faster than ever—reshaping how the industry approaches assay development, validation, and clinical trial execution. ICON’s Thanh-Long Nguyen will join the upcoming Bioanalysis Zone panel to exp...

Long‑acting injectables have reshaped HIV treatment, but they still fall short of overcoming the fundamental limitations of ART. Our latest article explores how next‑generation approaches are moving us closer to the poss...

Attending the World Vaccine Congress? Join ICON’s Dinah Knotts-Keeterle as she discusses ‘AI and the future of vaccine studies from reaction to readiness’. Learn more on 1 April at 12:10 pm. https://ow.ly/9Uk050Yr8VL